Skip to main content
Full access
Letters to the Editor
Published Online: 1 February 2017

Data Selection Importance in the Study of the Association Between Maternal Smoking During Pregnancy and Schizophrenia: Response to Meier et al.

To the Editor: We appreciate the comments of Meier et al. as they give us an opportunity to further clarify some key design elements of our study. We do not believe that the evidence these authors present is adequate to conclude that maternal smoking during pregnancy is not an independent risk factor for schizophrenia. First, while their sample was also a national cohort and was large, they used maternal self-report data on smoking, which are not considered to be reliable, and such misclassification most likely biased the association toward the null in the main analysis. It is for this reason that we used serum cotinine, a reliable biomarker of maternal smoking, in our study. Based on our studies, nearly 8% of women do not disclose their smoking during pregnancy (1). Second, this misclassification is also likely to have diminished the magnitude of association calculated from sibling comparisons considered to be differentially exposed and unexposed to smoking during pregnancy based on maternal report. Third, our results persisted following adjustment for both maternal and paternal psychopathology as well as other confounding factors that are related to smoking, suggesting that familial or genetic vulnerability did not account for the associations that we observed.

Reference

1.
Tikkanen M, Surcel HM, Bloigu A, et al: Self-reported smoking habits and serum cotinine levels in women with placental abruption. Acta Obstet Gynecol Scand 2010; 89:1538–1544

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 188
PubMed: 28142274

History

Accepted: October 2016
Published online: 1 February 2017
Published in print: February 01, 2017

Keywords

  1. Biological Markers
  2. Schizophrenia
  3. Epidemiology
  4. Psychoactive Substance Use Disorder

Authors

Details

Solja Niemelä, M.D., Ph.D.
From the Research Unit of Clinical Neuroscience, University of Oulu, Oulu, Finland, and the Department of Psychiatry, Lapland Hospital District, Rovaniemi, Finland; the Department of Child Psychiatry, Faculty of Medicine, University of Turku, and Turku University Hospital, Turku, Finland; the National Institute for Health and Welfare, Oulu, Finland; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York; and the Departments of Biostatistics and Epidemiology, Columbia University Mailman School of Public Health, New York.
Andre Sourander, M.D., Ph.D.
From the Research Unit of Clinical Neuroscience, University of Oulu, Oulu, Finland, and the Department of Psychiatry, Lapland Hospital District, Rovaniemi, Finland; the Department of Child Psychiatry, Faculty of Medicine, University of Turku, and Turku University Hospital, Turku, Finland; the National Institute for Health and Welfare, Oulu, Finland; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York; and the Departments of Biostatistics and Epidemiology, Columbia University Mailman School of Public Health, New York.
Heljä-Marja Surcel, Ph.D.
From the Research Unit of Clinical Neuroscience, University of Oulu, Oulu, Finland, and the Department of Psychiatry, Lapland Hospital District, Rovaniemi, Finland; the Department of Child Psychiatry, Faculty of Medicine, University of Turku, and Turku University Hospital, Turku, Finland; the National Institute for Health and Welfare, Oulu, Finland; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York; and the Departments of Biostatistics and Epidemiology, Columbia University Mailman School of Public Health, New York.
Susanna Hinkka-Yli-Salomäki, Ph.Lic.
From the Research Unit of Clinical Neuroscience, University of Oulu, Oulu, Finland, and the Department of Psychiatry, Lapland Hospital District, Rovaniemi, Finland; the Department of Child Psychiatry, Faculty of Medicine, University of Turku, and Turku University Hospital, Turku, Finland; the National Institute for Health and Welfare, Oulu, Finland; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York; and the Departments of Biostatistics and Epidemiology, Columbia University Mailman School of Public Health, New York.
Ian W. McKeague, Ph.D.
From the Research Unit of Clinical Neuroscience, University of Oulu, Oulu, Finland, and the Department of Psychiatry, Lapland Hospital District, Rovaniemi, Finland; the Department of Child Psychiatry, Faculty of Medicine, University of Turku, and Turku University Hospital, Turku, Finland; the National Institute for Health and Welfare, Oulu, Finland; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York; and the Departments of Biostatistics and Epidemiology, Columbia University Mailman School of Public Health, New York.
Keely Cheslack-Postava, Ph.D.
From the Research Unit of Clinical Neuroscience, University of Oulu, Oulu, Finland, and the Department of Psychiatry, Lapland Hospital District, Rovaniemi, Finland; the Department of Child Psychiatry, Faculty of Medicine, University of Turku, and Turku University Hospital, Turku, Finland; the National Institute for Health and Welfare, Oulu, Finland; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York; and the Departments of Biostatistics and Epidemiology, Columbia University Mailman School of Public Health, New York.
Alan S. Brown, M.D., M.P.H.
From the Research Unit of Clinical Neuroscience, University of Oulu, Oulu, Finland, and the Department of Psychiatry, Lapland Hospital District, Rovaniemi, Finland; the Department of Child Psychiatry, Faculty of Medicine, University of Turku, and Turku University Hospital, Turku, Finland; the National Institute for Health and Welfare, Oulu, Finland; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York; and the Departments of Biostatistics and Epidemiology, Columbia University Mailman School of Public Health, New York.

Funding Information

The authors’ disclosures accompany the original article.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share